Tibial plateau leveling osteotomy in a llama with a ruptured cranial cruciate ligament     

Ray WM  Gustafson SB  Huber MJ 《Journal of the American Veterinary Medical Association》2004,225(11):1739-42, 1702

A 3-year-old 155-kg (342-lb) castrated male llama was examined because of left hind limb lameness of acute onset. A diagnosis of cranial cruciate ligament and medial collateral ligament rupture was made, and tibial plateau leveling osteotomy was recommended. The tibial plateau leveling osteotomy procedure was performed as described for dogs, except that 2 orthopedic plates were used to stabilize the osteotomy because of the size of the llama. The medial collateral ligament was sutured and reinforced with 2 strands of size-2 polypropylene placed in a figure-8 fashion between cancellous bone screws in the femur and tibia. Four days after surgery, failure of the medial collateral ligament repair was evident. Approximately 3.5 years after surgery, the llama was reexamined. The owners reported that the llama had full use of its left hind limb, and only mild lameness (grade 1 of 5) was evident. Results suggest that tibial plateau leveling osteotomy may be applicable in camelids with rupture of the cranial cruciate ligament. However, additional study is needed before tibial plateau leveling osteotomy can be routinely recommended. In particular, additional information is needed on the tibial plateau slope in healthy camelids, the role of the fibula in tibial plateau leveling osteotomy procedures, and the prevalence of cranial cruciate ligament rupture in camelids.  相似文献   

Radiation therapy for the treatment of urethral sarcoma in a cria     

Gustafson NR  Severidt J  Van Metre DC  Schultheiss PC  Larue SM  Callan RJ 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2005,19(2):271-274

  相似文献   

Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats,cats with chronic kidney disease,and cats with liver disease          下载免费PDF全文

R. L. Fitzpatrick  L. A. Wittenburg  R. J. Hansen  D. L. Gustafson  J. M. Quimby 《Journal of veterinary pharmacology and therapeutics》2016,39(4):350-355

Ondansetron, a 5‐HT₃ receptor antagonist, is an effective anti‐emetic in cats. The purpose of this study was to compare pharmacokinetics of subcutaneous (SQ) ondansetron in healthy geriatric cats to cats with chronic kidney disease (CKD) or liver disease using a limited sampling strategy. 60 cats participated; 20 per group. Blood was drawn 30 and 120 min following one 2 mg ( mean 0.49 mg/kg , range 0.27–1.05 mg/kg ) SQ dose of ondansetron. Ondansetron concentrations were measured by liquid chromatography coupled to tandem mass spectrometry. Drug exposure represented as area under the curve (AUC) was predicted using a limited sampling approach based on multiple linear regression analysis from previous full sampling studies, and clearance (CL/F) estimated using noncompartmental methods. Kruskal–Wallis anova was used to compare parameters between groups. Mean AUC (ng/mL·h) of subcutaneous ondansetron was 301.4 (geriatric), 415.2 (CKD), and 587.0 (liver). CL/F (L/h/kg) of SQ ondansetron was 1.157 (geriatric), 0.967 (CKD), and 0.795 (liver). AUC was significantly higher in liver and CKD cats when compared to geriatric cats (P < 0.05). CL/F in liver cats was significantly decreased (P < 0.05) compared to geriatric cats. In age‐matched subset analysis, AUC and CL/F in liver cats remained significantly different from geriatric cats.  相似文献   

Estimating diagnostic test accuracy for infectious salmon anaemia virus in Maine, USA     

Gustafson L  Ellis S  Bouchard D  Robinson T  Marenghi F  Warg J  Giray C 《Journal of fish diseases》2008,31(2):117-125

  相似文献   

The past and future of modeling forest dynamics: from growth and yield curves to forest landscape models     

Stephen R. Shifley  Hong S. He  Heike Lischke  Wen J. Wang  Wenchi Jin  Eric J. Gustafson  Jonathan R. Thompson  Frank R. ThompsonIII  William D. Dijak  Jian Yang 《Landscape Ecology》2017,32(7):1307-1325

  相似文献   

Modeling forest landscapes in a changing climate: theory and application     

Hong S. He  Eric J. Gustafson  Heike Lischke 《Landscape Ecology》2017,32(7):1299-1305

  相似文献   

Oral,subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats     

J. M. Quimby  R. C. Lake  R. J. Hansen  P. J. Lunghofer  D. L. Gustafson 《Journal of veterinary pharmacology and therapeutics》2014,37(4):348-353

Ondansetron is a 5‐HT₃ receptor antagonist that is an effective anti‐emetic in cats. The purpose of this study was to evaluate the pharmacokinetics of ondansetron in healthy cats. Six cats with normal complete blood count, serum biochemistry, and urinalysis received 2 mg oral (mean 0.43 mg/kg), subcutaneous (mean 0.4 mg/kg), and intravenous (mean 0.4 mg/kg) ondansetron in a cross‐over manner with a 5‐day wash out. Serum was collected prior to, and at 0.25, 0.5, 1, 2, 4, 8, 12, 18, and 24 h after administration of ondansetron. Ondansetron concentrations were measured using liquid chromatography coupled to tandem mass spectrometry. Noncompartmental pharmacokinetic modeling and dose interval modeling were performed. Repeated measures anova was used to compare parameters between administration routes. Bioavailability of ondansetron was 32% (oral) and 75% (subcutaneous). Calculated elimination half‐life of ondansetron was 1.84 ± 0.58 h (intravenous), 1.18 ± 0.27 h (oral) and 3.17 ± 0.53 h (subcutaneous). The calculated elimination half‐life of subcutaneous ondansetron was significantly longer (P < 0.05) than oral or intravenous administration. Subcutaneous administration of ondansetron to healthy cats is more bioavailable and results in a more prolonged exposure than oral administration. This information will aid management of emesis in feline patients.  相似文献   

Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors     

Selting KA  Wang X  Gustafson DL  Henry CJ  Villamil JA  McCaw DL  Tate D  Beittenmiller M  Garnett C  Robertson JD 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2011,25(4):909-915

Background: Satraplatin is the 1st orally bioavailable platinum anticancer drug. Objective: Our objectives were to evaluate efficacy in vitro against a canine cancer cell line, to determine the maximally tolerated dose (MTD) of satraplatin in tumor‐bearing dogs, to identify the dose‐limiting and other toxicities in dogs, and to record pharmacokinetics (PK). Animals: Dogs with macro‐ or microscopic malignant neoplasia. Methods: D17 canine osteosarcoma cells first were evaluated in a clonogenic survival assay. Then, dogs with a diagnosis of malignant neoplasia were prospectively entered in standard 3 + 3 cohorts. Additional patients were entered at the MTD to assess efficacy. Total and free platinum (by ultrafiltrate) concentrations were determined with inductively coupled plasma mass spectroscopy. Results: Satraplatin inhibited clonogenic survival in vitro at clinically relevant and achievable concentrations. Twenty‐three dogs were treated, 14 with PK evaluation. The MTD was 35 mg/m²/d for 5 days, repeated every 3–4 weeks. Bioavailability was 41%. PK variables (mean ± SD) at the MTD included T_max 1.8 (± 0.7) hours, C_max 72 (± 26) ng/mL, area under concentration (AUC)_{0–24 h} 316 (± 63) h × ng/mL, and MRT 7 (± 1.3) hours. Higher AUC after the 5th versus the 1st dose suggested drug accumulation. Interestingly, platelets consistently reached nadir sooner than did neutrophils (day 14 versus 19). Myelosuppression was dose‐limiting and gastrointestinal toxicity was mild. Conclusions and Clinical Importance: Satraplatin was well tolerated in tumor‐bearing dogs, thus warranting further investigation in a phase II trial.  相似文献   

Studies on the pharmacokinetics and pharmacodynamics of mirtazapine in healthy young cats     

Quimby JM  Gustafson DL  Samber BJ  Lunn KF 《Journal of veterinary pharmacology and therapeutics》2011,34(4):388-396

Mirtazapine pharmacokinetics was studied in 10 healthy cats. Blood was collected before, and at intervals up to 72 h after, oral dose of 3.75 mg (high dose: HD) or 1.88 mg (low dose: LD) of mirtazapine. Liquid chromatography coupled to tandem mass spectrometry was used to measure mirtazapine, 8-hydroxymirtazapine and glucuronide metabolite concentrations. Noncompartmental pharmacokinetic modeling was performed. Median half-life was 15.9 h (HD) and 9.2 h (LD). Using Mann-Whitney analysis, a statistically significant difference between the elimination half-life, clearance, area under the curve (AUC) per dose, and AUC(∞) /dose of the groups was found. Mirtazapine does not appear to display linear pharmacokinetics in cats. There was no significant difference in glucuronidated metabolite concentration between groups. Pharmacodynamics was studied in 14 healthy cats administered placebo, LD and HD mirtazapine orally once in a crossover, blinded trial. In comparison with placebo, cats ingested significantly more food when mirtazapine was administered. No difference in food ingestion was seen between HD and LD, but significantly more behavior changes were seen with the HD. Limited serum sampling during the pharmacodynamic study revealed drug exposure comparable with the pharmacokinetic study, but no correlation between exposure and food consumed. Mirtazapine (LD) was administered daily for 6 days with no drug accumulation detected.  相似文献   

Alterations of Drug Metabolism in Critically Ill Animals     

Eileen S. Hackett  Daniel L. Gustafson  PhD 《Veterinary Clinics of North America: Small Animal Practice》2011,41(4):805-815

  相似文献